Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Advanced Melanoma Receiving Post-progression Dual Immune Checkpoint Inhibitor Therapy

NCT05779423 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT05779423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05779423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Advanced Melanoma Receiving Post-progression Dual Immune Checkpoint Inhibitor Therapy
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
September 23, 2023
Completion date
January 1, 2028
Enrollment
37 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma, skin cancer